We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MSDL:NYSEMorgan Stanley Direct Lending Fund Analysis

Data as of 2026-05-29 - not real-time

$15.28

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

MSDL trades at $15.28, just below its 20‑day SMA of 15.30 and comfortably above the identified support of $14.72, while remaining under the $15.85 resistance. The RSI of 53.3 signals a neutral stance, and a bearish MACD histogram reinforces a short‑term downside bias despite stable volume. With a low beta of ~0.58 and 30‑day volatility near 18.6%, the fund exhibits modest market sensitivity, and the extreme‑greed sentiment (FGI 93.36) reflects strong investor optimism.
Yield and valuation metrics are compelling: an 11.78% dividend yield, forward P/E of 8.4 and price‑to‑book of 0.77 suggest a cheap, income‑rich investment, and the fund currently shows no discount or premium. Recent earnings missed expectations due to rate‑cut impacts on its floating‑rate loan portfolio, yet management reports stable credit performance and improving lender economics, providing a cautiously optimistic outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings miss
  • Stable credit performance
  • High dividend yield

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Attractive forward P/E
  • Discount stability
  • Improving lender economics

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Dividend sustainability
  • Potential interest‑rate volatility
  • Sector credit quality

Key Metrics & Analysis

Closed-End Fund Metrics

Market Price15.28
Discount/Premium0.00%
Discount TrendStable

Technical Analysis

TrendNeutral
RSI53.3
Support$14.72
Resistance$15.85
MA 20$15.30
MA 50$14.92
MA 200$16.22
MACDBearish
VolumeStable
Fear & Greed Index93.36

Risk Assessment

Beta0.59
Volatility18.56%
Sector RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.